TMS for Complex Regional Pain Syndrome

Transcranial Magnetic Stimulation (TMS) for Complex Regional Pain Syndrome (CRPS)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03137472

Enrollment

Registered

2017-05-02

Start date

2017-04-24

Completion date

2028-06-29

Last updated

2026-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complex Regional Pain Syndromes

Keywords

TMS, CRPS, Sham

Brief summary

The aim of the current study is to assess the efficacy of TMS in the treatment of Complex Regional Pain Syndrome (CRPS). It is hypothesized that participants who receive TMS (Group 1) relative to sham treatment (Group 2) once daily for two days will demonstrate a greater improvement in CRPS-related pain and other associated symptomology (i.e., cognitive, emotional and physical) compared to baseline. Participants will be followed until they reach their baseline for two consecutive weeks to assess safety and duration of symptom alleviation.

Interventions

DEVICETranscranial Magnetic Stimulation (TMS)

The Magventure TMS stimulator will be used to perform intermittent theta burst followed by high frequency Transcranial Magnetic Stimulation (TMS).

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Masking description

Single, blinding of participant

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Age 18-70 * Diagnosis of CRPS (complex regional pain syndrome) for at least 3 months * Average pain level reported on Numerical Rating Scale meets entry criteria * Ability to perform the experimental task and procedures.

Exclusion criteria

* MRI contraindication (metal implants or devices, claustrophobia) * TMS Contraindication (eg metal implant or devices near the site of stimulation) * History of epilepsy * History of a psychological or psychiatric disorder that would interfere with study procedures, at the discretion of the researcher. * Neurologic illness that would interfere with brain integrity * Current medical condition or medication use that would interfere with study procedures or data integrity, at the discretion of the researcher. * Currently pregnant or planning to become pregnant. * On going legal action or disability claim.

Design outcomes

Primary

Measure	Time frame	Description
Change in Pain	1 week follow-up compared to baseline	Decrease in CRPS-related Pain Ratings
Duration of Pain Relief	Duration from last treatment until pain returns - up to an estimate of 6 months	Duration of decreased CRPS-related pain ratings, measured as a length of time until pain returns for two consecutive weeks

Secondary

Measure	Time frame	Description
Change in Pain-related Symptomology	Duration from last treatment until pain returns - up to an estimate of 6 months	Decreases in Pain-related Symptomology (i.e., cognitive, emotional and physical)

Countries

United States

Contacts

CONTACTOmar Altirkawi

omar97@stanford.edu(650) 497-0485

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 24, 2026